Abstract | PURPOSE OF REVIEW: A complex network of hormones and other effectors characterize the hypermetabolic response in critical illness; these mediators work together to induce numerous pathophysiologic alterations. Increased incidence of infection, multiorgan failure, long-term debilitation, delays in rehabilitation, and death result from an inability to meet the prohibitively elevated protein and energy requirements, which occur during illness and can persist for several years. Pharmacologic interventions have been successfully utilized to attenuate particular aspects of the hypermetabolic response; these modalities are a component of managing critically ill patients - including those patients with severe burns. Here, we review recent advances in pharmacologically attenuating the hypermetabolic and catabolic responses. RECENT FINDINGS: SUMMARY: Profound metabolic derangements occur in critically ill patients; this hypermetabolic response is a major contributor to adverse outcomes. Despite the pharmacological therapies currently available to counteract this devastating cascade, future studies are warranted to explore new multimodality agents that will counteract these effects while maintaining glycemic control and preventing unfavorable complications.
|
Authors | Mile Stanojcic, Celeste C Finnerty, Marc G Jeschke |
Journal | Current opinion in critical care
(Curr Opin Crit Care)
Vol. 22
Issue 4
Pg. 325-31
(08 2016)
ISSN: 1531-7072 [Electronic] United States |
PMID | 27272101
(Publication Type: Journal Article, Review)
|
Chemical References |
- Adrenergic beta-Antagonists
- Anabolic Agents
- Insulin
- Oxandrolone
- Propranolol
|
Topics |
- Adrenergic beta-Antagonists
(administration & dosage, therapeutic use)
- Anabolic Agents
(administration & dosage, therapeutic use)
- Critical Care
(methods)
- Critical Illness
(therapy)
- Humans
- Insulin
(administration & dosage)
- Oxandrolone
(administration & dosage)
- Propranolol
(administration & dosage)
|